Firazorexton
Firazorexton (; development code TAK-994) is an experimental orexin 2 (OX2) receptor agonist first described in a 2019 patent filed by Takeda Pharmaceutical Company. Firazorexton was studied by Takeda for the treatment of narcolepsy. It is a small-molecule and orally active compound and acts as a highly selective agonist of the orexin receptor 2 (OX2) with >700-fold selectivity over the orexin receptor 1 (OX1). Firazorexton is related to danavorexton (TAK-925). The compound reached phase 2 clinical trials for narcolepsy. However, clinical development was discontinued in October 2021 for safety reasons. See also
 Orexin receptor § Agonists
 List of investigational sleep drugs § Orexin receptor agonists

References

Tertiary alcohols
Abandoned drugs
Fluoroarenes
Orexin receptor agonists
Pyrrolidines
Sulfonamides
Biphenyls